文献速递淋巴瘤

miR-125a与miR-34a表达可预测慢性淋巴细胞白血病患者的Richter综合征

miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients.
PubMed 文献 · Blood · 2018-09-21

研究比较49例后来发生Richter综合征(RS)的慢性淋巴细胞白血病(CLL)患者与59例未发生RS患者的微小RNA表达,发现miR-125a-5p高表达或miR-34a-5p低表达可预测约50%的RS,假阳性率约9%;预测发生RS者miR-125a-5p表达增加约20倍或miR-34a-5p表达降低约21倍。

要点

  • 高表达miR-125a-5p或低表达miR-34a-5p可预测约50%的Richter综合征,假阳性率约9%。
  • 预测发生RS的CLL患者miR-125a-5p表达增加约20倍或miR-34a-5p表达降低约21倍。
  • miR-125a-5p与miR-34a-5p可能成为有价值的RS预测标志物。

核心结论

  • miR-125a-5p高表达或miR-34a-5p低表达可预测约50%的Richter综合征,假阳性率约9%。
  • miR-125a-5p和miR-34a-5p可能成为有价值的Richter综合征预测标志物,并有可能为医生提供信息以指示CLL患者的最佳治疗策略。

研究设计与样本

  • 比较49例后来发生Richter综合征的CLL患者与59例未发生Richter综合征的CLL患者的微小RNA表达水平。

主要发现

  • 与未预测发生RS的CLL患者相比,预测发生RS的CLL患者miR-125a-5p表达增加约20倍。
  • 与未预测发生RS的CLL患者相比,预测发生RS的CLL患者miR-34a-5p表达降低约21倍。
  • 高表达miR-125a-5p或低表达miR-34a-5p可预测约50%的Richter综合征,假阳性率约9%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. It is characterized by the accumulation of CD19+/CD5+ lymphocytes and can have variable outcomes. Richter syndrome (RS) is a lethal complication in CLL patients that results in aggressive B-cell lymphomas, and there are no tests to predict its occurrence. Because alterations in microRNA expression can predict the development and progression of several cancers, we investigated whether dysregulation of specific microRNAs can predict RS in CLL patients. Thus, we compared microRNA expression levels in samples from 49 CLL patients who later developed RS with samples from 59 CLL patients who did not. We found that high expression of miR-125a-5p or low expression of miR -34a-5p can predict ∼50% of RS with a false positive rate of ∼9%. We found that CLL patients predicted to develop RS show either an increase of miR-125a-5p expression (∼20-fold) or a decrease of miR-34a-5p expression (∼21-fold) compared with CLL patients that are not predicted to develop RS. Thus, miR-125a-5p and miR-34a-5p can be valuable predictor markers of RS and have the potential to provide physicians with information that can indicate the best therapeutic strategy for CLL patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Balatti V, Tomasello L, Rassenti LZ, et al. miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 2018. PMID: 30242085. doi:10.1182/blood-2018-04-845115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。